Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for Sjögren’s syndrome with interstitial lung disease
ChiCTR2600130591Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept in Sjögren's syndrome (SS) and interstitial lung disease (ILD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Forced vital capacity (FVC), Diffusing capacity of the lungs for carbon monoxide (DLCO) and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Sjögren's syndrome (SS)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2600130591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130591.